Literature DB >> 21160682

Current advances in the understanding of coronary vasospasm.

Ming-Jui Hung1.   

Abstract

Recent years have witnessed progress in our understanding of coronary vasospasm (CVS). It is evident that this is not only an East Asian but also a global disease associated with significant symptoms and possible lethal sequelae for afflicted individuals. A correct diagnosis depends on the understanding of pathogenesis and symptomatology of CVS. With the correct diagnosis, we can manage CVS patients effectively and promptly, providing optimal patient safety. Advances in our understanding of interactions between inflammation, endothelium, and smooth muscle cells have led to substantial progress in understanding the pathogenesis of symptoms in CVS and have provided some insights into the basic etiology of this disorder in some patient subpopulations. We look forward to a time when therapy will address pathophysiology and perhaps, even the primary etiology.

Entities:  

Keywords:  Coronary vasospasm; Endothelial nitric oxide synthase; Inflammation; Nitric oxide; Rho-kinase

Year:  2010        PMID: 21160682      PMCID: PMC2998866          DOI: 10.4330/wjc.v2.i2.34

Source DB:  PubMed          Journal:  World J Cardiol


  99 in total

1.  Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity C-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease.

Authors:  Ming-Jui Hung; Wen-Jin Cherng; Chi-Wen Cheng; Ning-I Yang
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

2.  Hyperventilation as a specific test for diagnosis of coronary artery spasm.

Authors:  K Nakao; M Ohgushi; M Yoshimura; K Morooka; K Okumura; H Ogawa; K Kugiyama; Y Oike; K Fujimoto; H Yasue
Journal:  Am J Cardiol       Date:  1997-09-01       Impact factor: 2.778

3.  T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm.

Authors:  M Nakayama; H Yasue; M Yoshimura; Y Shimasaki; K Kugiyama; H Ogawa; T Motoyama; Y Saito; Y Ogawa; Y Miyamoto; K Nakao
Journal:  Circulation       Date:  1999-06-08       Impact factor: 29.690

4.  "Variant" angina: one aspect of a continuous spectrum of vasospastic myocardial ischemia. Pathogenetic mechanisms, estimated incidence and clinical and coronary arteriographic findings in 138 patients.

Authors:  A Maseri; S Severi; M D Nes; A L'Abbate; S Chierchia; M Marzilli; A M Ballestra; O Parodi; A Biagini; A Distante
Journal:  Am J Cardiol       Date:  1978-12       Impact factor: 2.778

5.  A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese.

Authors:  M Yoshimura; H Yasue; M Nakayama; Y Shimasaki; H Sumida; S Sugiyama; K Kugiyama; H Ogawa; Y Ogawa; Y Saito; Y Miyamoto; K Nakao
Journal:  Hum Genet       Date:  1998-07       Impact factor: 4.132

6.  Supersensitive dilator response to nitroglycerin but not to atrial natriuretic peptide in spastic coronary arteries in coronary spastic angina.

Authors:  K Kugiyama; M Ohgushi; S Sugiyama; T Motoyama; H Kawano; O Hirashima; H Yasue
Journal:  Am J Cardiol       Date:  1997-03-01       Impact factor: 2.778

7.  Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.

Authors:  Y Igarashi; M Yamazoe; A Shibata
Journal:  Am Heart J       Date:  1991-04       Impact factor: 4.749

8.  Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina.

Authors:  T Motoyama; H Kawano; K Kugiyama; O Hirashima; M Ohgushi; R Tsunoda; Y Moriyama; Y Miyao; M Yoshimura; H Ogawa; H Yasue
Journal:  J Am Coll Cardiol       Date:  1998-11-15       Impact factor: 24.094

9.  Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study.

Authors:  Peter Ong; Anastasios Athanasiadis; Stephan Hill; Holger Vogelsberg; Matthias Voehringer; Udo Sechtem
Journal:  J Am Coll Cardiol       Date:  2008-08-12       Impact factor: 24.094

10.  Comparison of peripheral monocyte counts in patients with and without coronary spasm and without fixed coronary narrowing.

Authors:  Ming-Jui Hung; Li-Tang Kuo; Chi-Wen Cheng; Chih-Ping Chang; Wen-Jin Cherng
Journal:  Am J Cardiol       Date:  2004-03-01       Impact factor: 2.778

View more
  6 in total

1.  Case report: acute coronary artery spasm in a patient in the setting of non-cardiac surgery.

Authors:  Ngozi Aikpokpo; Stephan Hill; Udo Sechtem
Journal:  Clin Res Cardiol       Date:  2012-04-12       Impact factor: 5.460

2.  Increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina.

Authors:  Ming-Jui Hung; Wen-Jin Cherng; Ming-Yow Hung; Li-Tang Kuo; Chi-Wen Cheng; Chao-Hung Wang; Ning-I Yang; James K Liao
Journal:  Atherosclerosis       Date:  2012-01-12       Impact factor: 5.162

3.  Ergonovine stress echocardiography: Recent experience and safety in our centre.

Authors:  Alejandro Cortell; Pedro Marcos-Alberca; Carlos Almería; José L Rodrigo; Leopoldo Pérez-Isla; Carlos Macaya; José Luis Zamorano
Journal:  World J Cardiol       Date:  2010-12-26

4.  Interleukin-6 promotor polymorphisms and coronary vasospastic angina in Han Chinese.

Authors:  Ying Wang; Gang Li; Ya-Min Su; Hai-Yan Pan; Hai-Hua Geng; Meng-Kan Fan; Min Pan
Journal:  Int J Clin Exp Med       Date:  2014-09-15

5.  Evaluation of coronary microvascular function in patients with vasospastic angina.

Authors:  Hiroki Teragawa; Naoya Mitsuba; Ken Ishibashi; Kenji Nishioka; Satoshi Kurisu; Yasuki Kihara
Journal:  World J Cardiol       Date:  2013-01-26

6.  Downregulated caveolin-1 expression serves a potential role in coronary artery spasm by inducing nitric oxide production in vitro.

Authors:  Xingmei Cao; Zhishuai Ye; Mingyu Jin; Shuai Yan; Xiantao Song; Rongchong Huang
Journal:  Exp Ther Med       Date:  2018-08-22       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.